Mostrar registro simples

dc.contributor.authorBerlitz, Simone Jacobuspt_BR
dc.contributor.authorReginatto, Paulapt_BR
dc.contributor.authorMachado, Gabriella da Rosa Montept_BR
dc.contributor.authorFuentefria, Alexandre Meneghellopt_BR
dc.contributor.authorMorisso, Fernando Dal Pontpt_BR
dc.contributor.authorContri, Renata Vidorpt_BR
dc.contributor.authorKülkamp-Guerreiro, Irene Clemespt_BR
dc.date.accessioned2023-06-17T03:37:32Zpt_BR
dc.date.issued2023pt_BR
dc.identifier.issn1999-4923pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/259111pt_BR
dc.description.abstractDermatomycosis is a common fungal infection, and its treatment is limited by few antifungal agents. Clioquinol (CQ) is an antiparasitic agent that has been studied for new uses, such as antifungal and antiviral applications. CQ was incorporated into a lipid-based nanocarrier as a new, promising option for dermatomycosis. This study aimed to develop a CQ-loaded lipid-based nanocarrier for cutaneous application and to evaluate its antifungal activity. CQ-loaded nanoformulation (LBN-CQ) was developed using the ultrasonication method, and the particle size, polydispersity index (PDI), pH, zeta potential, and drug content were monitored for 45 days. To evaluate antifungal activity, broth microdilution and a time-kill assay were performed. LBN-CQ presented a particle size of 91 3 nm and PDI of 0.102 0.009. The zeta potential and pH values were 􀀀9.7 2.0 mV and 6.0 0.1, respectively. The drug content was 96.4 2.3%, and the encapsulation efficiency was 98.4%. LBN-CQ was able to reduce the minimum inhibitory concentration (MIC) in a 2-fold or 4-fold manner in most of the tested strains. Additionally, LBN-CQ presented stable fungistatic action that was not concentration- or time-dependent. In conclusion, the developed CQ-loaded nanocarrier is a promising treatment for skin fungal infections and a promising candidate for future randomized clinical trials.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofPharmaceutics. Basel. Vol. 15, n. 2 (2023), 531, 14 p.pt_BR
dc.rightsOpen Accessen
dc.subjectDermatomicosespt_BR
dc.subjectCutaneous diseasesen
dc.subjectClioquinolen
dc.subjectAntifúngicospt_BR
dc.subjectNanotecnologiapt_BR
dc.subjectNanotechnologyen
dc.subjectAntifungalen
dc.subjectClioquinolpt_BR
dc.subjectDermatomycosisen
dc.titleDevelopment of a clioquinol nanocarrier as a new, promising option for the treatment of dermatomycosispt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001163288pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples